SCHEMBL5547704

SCHEMBL5547704

[CH2]N1CC=C(c2ccccc2OC)CC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TNKS O95271 1/20 0.46
TNKS2 Q9H2K2 1/20 0.46
PARP1 P09874 1/20 0.43
PTGS2 P35354 1/20 0.42
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
CACNA1G O43497 1/20 0.40
KCNH2 Q12809 1/20 0.40
HTR7 P34969 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
CCNT1 O60563 2/20 0.39
CDK9 P50750 2/20 0.39
APP P05067 1/20 0.39
MAPT P10636 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547709 0.83 QDPR (0.54) TNKSTNKS2L3MBTL1
SCHEMBL5536925 0.81 SLC6A4 (0.44) CCNT1CDK9
SCHEMBL13801237 0.80 TNKS (0.51) TNKSTNKS2PARP1PTGS2PPARG
SCHEMBL20993990 0.77 MAPT (0.50) TNKSTNKS2PARP1PPARGPPARA
SCHEMBL2396688 0.76 HTR1A (0.57) PARP1PPARGPPARACCNT1CDK9
SCHEMBL7549123 0.76 MAPT (0.49) TNKSTNKS2PARP1PPARGPPARA
SCHEMBL186070 0.73 CCNT1 (0.52) TNKSTNKS2PPARGPPARACACNA1G
SCHEMBL5546722 0.72 SIGMAR1 (0.47) MAPT
SCHEMBL10827443 0.72 PTGS2 (0.45) PTGS2HTR7CHRM2CHRM4CHRM5
SCHEMBL3986140 0.72 ALDH1A1 (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TNKS 3905/4885TNKS2 3109/4885PARP1 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.